NCT00658671View on ClinicalTrials.gov

A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

June 30, 2012

Conditions
Advanced Cancer
Interventions
DRUG

ENMD-2076

Capsules, daily dosing in 28 day cycles

Trial Locations (2)

80045

University of Colorado Hospital, Aurora

Unknown

Dana Farber/Harvard Cancer Center, Boston

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY